<DOC>
	<DOCNO>NCT02889796</DOCNO>
	<brief_summary>The primary objective study evaluate effect filgotinib versus placebo adult active rheumatoid arthritis ( RA ) inadequate response methotrexate ( MTX ) .</brief_summary>
	<brief_title>Filgotinib Combination With Methotrexate Adults With Moderately Severely Active Rheumatoid Arthritis Who Have Inadequate Response Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Have diagnosis RA ( 2010 ACR/EULAR criterion ) , ACR functional class IIII . Have ≥ 6 swollen joint ( swollen joint count base 66 joint ( SJC66 ) ) ≥ 6 tender joint ( tender joint count base 68 joint ( TJC68 ) ) screen Day 1 . Ongoing treatment stable dose MTX Previous treatment janus kinase ( JAK ) inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>